Biodesix Projects 2026 Revenue Between $101M and $103M Amid Growing Test Volumes
Biodesix (BDSX) reported strong third-quarter performance, highlighted by a 10% increase in total revenue and a significant 24% growth in test volumes. The company's diagnostic testing segment saw a 16% revenue rise, while maintaining a robust gross margin of 81%. Looking ahead to 2026, management has provided revenue guidance in the range of $101 million to $103 million. To support this growth trajectory, the company plans to expand its commercial presence, aiming to exit 2026 with approximately 115 sales representatives.
Tickers: $BDSX
Topics: diagnostic testing gross margin quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story Biodesix Reports 10% Revenue Growth in Q3 2026 Amid Sales Turnover Challenges (2 articles)